問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Infectious Disease

Division of Others-

Division of General Internal Medicine

Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch

Division of Hematology & Oncology

更新時間：2023-09-19

柯博升-, -
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

114Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

柯博升

List

178Cases

2018-09-01 - 2026-10-02

Phase III

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS) IN ESA NAiVE SUBJECTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS

  • Condition/Disease

    Myelodysplastic Syndromes

  • Test Drug

    Luspatercept; Epoetin alfa

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting4Sites

2016-05-10 - 2022-05-31

Phase III

A phase 3, randomized, double-blind, placebo-controlled study to compare efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in subjects with acute myeloid leukemia in complete remission.

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Oral Azacitidine (CC-486)

Participate Sites
6Sites

Terminated5Sites

2017-07-18 - 2024-06-30

Phase III

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

  • Condition/Disease

    Acute Myeloid Leukemia with an IDH1 Mutation

  • Test Drug

    Ivosidenib (AG-120);Azacitidine

Participate Sites
8Sites

Recruiting6Sites

蕭惠樺
Kaohsiung Municipal Gangshan Hospital

未分科

2016-05-01 - 2019-09-30

Phase I

A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in Combination with Azacitidine in Adult East Asian Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

  • Condition/Disease

    Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

  • Test Drug

    Pevonedistat (MLN4924, TAK-924)

Participate Sites
2Sites

Terminated2Sites

2016-03-01 - 2023-03-01

Phase III

Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma

  • Condition/Disease

    Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma

  • Test Drug

    Lenalidomide (CC-5013)

Participate Sites
6Sites

Terminated5Sites

2015-08-01 - 2020-03-31

Phase III

A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215 Down-sized Tablets 40 mg

Participate Sites
9Sites

Terminated8Sites

2011-10-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2021-08-01 - 2021-09-27

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-09-01 - 2025-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-01-01 - 2023-12-31

Phase I

A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations

  • Condition/Disease

    Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations

  • Test Drug

    LY3410738

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

1 12 13 14 15 16 18
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB